Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
US8876761B2 · kind B2 · utility
Assignee
Inventors
- Thomas Albrecht
- Jeffrey L. Aldridge
- Sean P. Conlon
- Michael S. Cropper
- Denzel Z. Herrera-Davis
- Daniel F. Dlugos, Jr.
- Jason L. Harris
- Christopher J. Hess
- Prasanna Malaviya
- Glenda C. Marsh
- Mark S. Ortiz
- Mark D. Overmyer
- Alessandro Pastorelli
- Galen C. Robertson
- Frederick E. Shelton, IV
- Michael J. Stokes
- James W. Voegele
- Lauren S. Weaner
- William B. Weisenburgh, II
- Christopher W. Widenhouse
- Tamara S. Vetro Widenhouse
- James A. Woodard, Jr.
- David C. Yates
- Mark S. Zeiner
- Andrew M. Zwolinski
Key dates
| Filing date | May 10, 2011 |
| Grant date | Nov 4, 2014 |
| Priority date | — |
| Expiry date | Sep 26, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N1/37205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and devices create an intestinal braking effect, are non-invasive or minimally invasive, and may be reversible. These methods and devices are accomplished via stabilized implantable systems and ingestible pills. In one embodiment, a method of producing satiety comprising the steps of accessing a gastrointestinal tract of a patient and implanting an intraintestinal therapeutic substance eluting implant. The implant is capable of eluting a satiety inducing substance selected from at least one of a nutrient, a specific satiety inducing bio-active substance, pancreatic polypeptides, free fatty acids, cholecystokinin, amino acids, glutamine, lipids, linoleic acid, or a combination thereof, from the implant into the gastrointestinal tract.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.